Modality
Degrader
MOA
IL-17i
Target
BCL-2
Pathway
Lipid Met
IgAN
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
Aug 2017
Phase 1Current
NCT03566261
341 pts·IgAN
2017-08→TBD·Completed
341 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P1/2
Complet…
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03566261 | Phase 1/2 | IgAN | Completed | 341 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-8550 | Roche | Approved | BCL-2 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 | |
| Bemaderotide | Revolution Medicines | Phase 3 | BCL-2 | |
| Nidaratamab | Krystal Biotech | Preclinical | RET |